Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Aug;96(33):e7781.
doi: 10.1097/MD.0000000000007781.

Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis

Xiaoping Zhang  1 , Zheng Ge, Baoan Chen, Ran Liu, Chong Gao
Affiliations
Meta-Analysis

Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis

Xiaoping Zhang et al. Medicine (Baltimore). 2017 Aug.

Abstract

This meta-analysis was performed to evaluate the efficacy and safety of fludarabine (F)-based regimen for the treatment of non-Hodgkin lymphoma (NHL) compared with other regimens with no F contained.PubMed, Embase, Cochrane Library, Wanfang, VIP, and CNKI databases were searched to identify eligible literatures. R software version 3.12 was used for statistical analysis. Odds ratio (OR) with 95% confidence interval (CI) were utilized to express the complete response, overall response and adverse events outcomes. Egger test was carried out to examine the publication bias and sensitivity analysis was performed to evaluate the stability of our results.Twelve eligible literatures consisting of 1587 patients were included in this study. Greater complete response (OR = 1.66, 95% CI: 0.98-2.80) and overall response (OR = 1.38, 95% CI: 0.85-2.24) were found for patients who received F-based regimen than those received other regimens, although the results were not statistically significant. In addition, F-based regimen was associated with significantly lower risk of adverse events compared with other regimens (OR = 0.46, 95% CI: 0.28-0.74). Results of subgroup analysis showed that significantly lower incidence was presented only for constipation among the 7 specific adverse events (OR = 0.03, 95% CI: 0.01-0.14).F-based chemotherapy regimen was an effective and well-tolerated treatment for patients with NHL.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow chart of study selection.
Figure 2
Figure 2
Forest plots of treatment effect for (A) complete response and (B) overall response.
Figure 3
Figure 3
Sensitivity analysis of treatment effect for (A) complete response and (B) overall response.
Figure 4
Figure 4
Funnel plot for (A) complete response and (B) overall response.
Figure 5
Figure 5
Forest plots of treatment effect for adverse events.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003;362:139–46. - PubMed
    1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848–57. - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375–90. - PMC - PubMed
    1. Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 2005;80:1087–97. - PubMed
    1. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261–71. - PMC - PubMed

Publication types

MeSH terms